·
Dinitrogen monoxide; Laughing gas;
Hyponitrous acid anhy-dride; Factitious air.
·
Nitrous oxide is a colourless gas
with a slightly sweetish odour and taste.
·
May also exist in the form of a
liquid or cubic crystals. Nitrous oxide is abundant in the atmosphere as a
result of bacterial decomposition of organic nitrogen compounds in soil.
■■As a sole agent, nitrous oxide is used intermittently to
provide analgesia for dental and obstetric procedures.
■■In combination with other agents, nitrous oxide is used as a
general anaesthetic.
■■It is also used as a foaming agent for whipped cream, to
make nitrates from alkali metals, as an oxidant for organic compounds, and in some
rocket fuel combinations. Consumer cans of whipped cream have been reported to
release up to 1.5 L of nitrous oxide. High concentrations of carbon dioxide and
fluorocarbons may also be released.
·
Nitrous oxide is a gas that acts as
a central nervous system depressant and can cause asphyxiation by oxygen
displace-ment.
·
It oxidizes cobalt in vitamin B12,
rendering it biologically inactive. This produces a deficiency in available
active B12 and the results mimic B12
deprivation states.
·
Nitrous oxide has been demonstrated
to be a partial agonist at mu, kappa, and sigma receptors of the endogenous
opioid system. This may explain the emetic and addictive proper- ties of
nitrous oxide. Naloxone appears to partially reverse nitrous oxide-induced
analgesia.
·
Nitrous oxide is 35 times more
soluble in blood than nitrogen. When it is inhaled, compliant
air-containingnitrogen. When it is inhaled, compliant air-containing spaces
such as the bowel will increase in size, while non- compliant spaces such as
eustachian tubes will increase in pressure. This can lead to bowel distension,
tympanic membrane rupture, etc.
·
Nitrous oxide has been reported to
cause mild hyperten- sion when used as an anaesthetic. Cardiac arrhythmias may
occur, and may be the result of hypoxia. Nausea and vomiting may occur.
·
Acute neurologic effects of
intoxication are primarily due to asphyxia. Signs and symptoms may include
headache, dizziness, and excitation that may progress to CNS depres- sion,
seizures, and death. Respiratory irritation may be noted. Interstitial
emphysema and pneumomediastinum have been reported following inhalation from
whippedcream dispensers.
· Nitrous oxide is thought to be a potential carcinogen based on animal studies.
·
Respiratory depression, increased
muscle tone, hyperten-sion, mydriasis, cardiovascular failure.
·
Chronic use (or abuse, especially by
hospital and dental personnel) can lead to bone marrow depression,
polyneu-ropathy, megaloblastic changes, and death. Chronic abuse can also cause
myeloneuropathy. Findings include ataxia, peripheral sensory neuropathy, and
weakness. Impotence has been reported as an early sensory complaint associ-ated
with nitrous oxide-induced myeloneuropathy Many of the neurological and
haematopoietic effects of nitrous oxide are believed to be due to the selective
inactivation of vitamin B12.
·
Bone marrow depression with resultant
leukopenia, throm-bocytopenia and severe megaloblastic anaemia has been noted
following chronic or intermittent inhalation of nitrous oxide.
·
Exposure to 50 to 70% nitrous oxide
for 3 hours can result n aplastic anaemia and death.
·
Inhalation of 40% nitrous oxide in
air can cause confusion and sedation, while an 80% level causes unconsciousness
in most individuals.
·
Removal from source of exposure. If
cough or difficulty in breathing develops, evaluate for hypoxia, respiratory
tract irritation, bronchitis, or pneumonitis.
·
Cerebral oedema and elevated
intracranial pressure (ICP) may occur. Emergent management includes head
eleva-tion and administration of mannitol; hyperventilation should be performed
if there is evidence of impending herniation.
·
Plasma nitrous oxide levels are not
clinically useful.
·
Case reports suggest that
administration of folate and vitamin B12
supplements may help reverse myeloneurop-athy associated with chronic nitrous
oxide abuse, although this has not been well studied.
·
Folinic acid, 30 mg, IV, for bone
marrow abnormalities.
·
Methionine-supplemented diet to
minimise neurologic damage.
·
Arrhythmias are generally secondary
to hypoxia and usually resolve with oxygenation. Therapy with antiarrhythmics
should be reserved for patients with arrhythmias that persist after adequate
oxygenation.
·
Monitor patient for signs of
bleeding and infection. Treatment is symptomatic and supportive. Folate
supple-mentation may reverse the bone marrow abnormalities associated with
nitrous oxide toxicity.
Supportive
measures:
o Treatment
of hypoxia.
o Control
of seizures.
o Treatment
of pulmonary oedema.
o Continuous
cardiac monitoring.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.